کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5502436 | 1400160 | 2016 | 9 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
The development of immunotherapy in older adults: New treatments, new toxicities?
ترجمه فارسی عنوان
توسعه ایمنوتراپی در افراد مسن تر: درمان های جدید، سمیت های جدید؟
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ORRPD-L1ICBPD1IRAERCCCTLA4Medical oncology - انکولوژی پزشکیimmunotherapy - ایمونوتراپیImmune checkpoint - بازرسی ایمنیoverall survival - بقای کلNSCLC - سرطان ریوی غیر سلول کوچکNon-small cell lung cancer - سرطان غیر سلول کوچک ریهToxicity - سمی بودنimmune-related adverse event - عوارض جانبی مرتبط با ایمنیAged - مسنNeoplasms - نئوپلاسمoverall response rate - نرخ پاسخ کلیRenal cell carcinoma - کارسینوم سلول کلیوی یا RCC
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
سالمندی
چکیده انگلیسی
Monoclonal antibodies targeting immune checkpoint molecules CTLA-4, PD-1 or PD-L1 are emerging as promising anticancer therapeutics in multiple cancer subtypes resulting in remarkable and long-lasting clinical responses. These immune checkpoint blockers (ICBs) have already obtained approval for the treatment of patients with metastatic melanoma, advanced/refractory non-small cell lung cancer and renal cell cancer. ICBs enhance immune responses against cancer cells but can also lead to inflammatory side effects called immune-related adverse events (irAEs). Such toxicities are distinct from those associated with traditional chemotherapeutic agents or molecularly targeted therapies. Although severe irAEs remain rare (~Â 10% of cases under monotherapy), they can become life-threatening if not anticipated and managed appropriately. As malignancies are frequently diagnosed in older patients, ICB treatment of elderly presents a unique challenge. However, the knowledge about efficacy and toxicity of these molecules in this specific population is limited, as most of the studies have involved a low number of older patients. In this review, we will discuss about the different ICB efficacy data available for older patients. We will then highlight the specific spectrum of immunotherapy toxicities and talk about their management in the context of older adults.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Geriatric Oncology - Volume 7, Issue 5, September 2016, Pages 325-333
Journal: Journal of Geriatric Oncology - Volume 7, Issue 5, September 2016, Pages 325-333
نویسندگان
Carole Helissey, Cécile Vicier, Stéphane Champiat,